Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery (IVAPAP)

25. September 2015 aktualisiert von: Davide Cattano, The University of Texas Health Science Center, Houston

A Double Blind, Randomized, Placebo-controlled Study to Investigate the Effectiveness of IV Acetominophen Administered During Functional Endoscopic Sinus Surgery in Reducing the Use of Opiates to Treat Postoperative Pain

The purpose of this study is to assess the use of IV acetaminophen (Ofirmev) as a and safe and efficacious agent in reducing post-operative pain; we hypothesize that its use will reduce post-operative pain when compared to a control group using the visual analogue score (VAS) analog pain scoring system.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Detaillierte Beschreibung

Unrelieved postoperative pain may result not only in suffering and discomfort, but may also lead to multiple physiological and psychological consequences which can contribute to adverse perioperative outcomes. Inadequate perioperative analgesia can potentially contribute to a higher incidence of myocardial ischemia. Additionally, the use of opioids has been associated with major side effects that can include impaired wound healing and delayed gastrointestinal (GI) motility that results in prolonged postoperative ileus.

Intravenous acetyl-para-aminophenol (APAP, also known as acetaminophen) is considered as the non-opioid analgesic of choice to treat postoperative mild and moderate pain, and has been demonstrated in several randomized trials to be both safe and effective at reducing acute post-operative pain in both children and adults. Furthermore, in the treatment of severe pain, it can reduce the need for opioid-analgesics while exhibiting a relatively limited side effect profile when compared to opioids and nonsteroidal anti-inflammatory drugs.

Chronic rhinosinusitis (CRS) describes a group of disorders characterized by inflammation of the nasal mucosa and/or paranasal sinuses for at least 12 consecutive weeks. In the United States, CRS affects approximately 30 million people, and represents 2% of the primary diagnoses in physician office visits, resulting in an estimated 200,000 sinus procedures annually. Patients suffering from CRS that is refractory to medical management complain of symptoms that include fatigue, headache, nasal drainage, facial pain and pressure, and decreased sense of smell. Functional endoscopic sinus surgery (FESS) represents a surgical approach to treating CRS that is unresponsive to medical management. Outcomes studies have identified FESS as efficacious at reducing the majority of symptoms related to CRS. Despite this, pain associated with CRS remains a significant co-morbidity that often is resistant to both medical and surgical management. Reducing the incidence and severity of acute post-operative pain is paramount to reducing the development of chronic pain that may exacerbate a patient's existing pain. The use of pre- and intra- operative IV acetaminophen thus serves as a unique pain management modality in this setting, as it has the potential for reducing post-operative complications and pain, with the additional benefit of minimal intraoperative bleeding, an undesirable complication often associated with FESS and with the use of non-steroidal anti-inflammatory drugs (NSAIDs).

The use of IV acetaminophen in ear, nose, and throat (ENT) surgery is not a novel endeavor. Indeed, studies have demonstrated the efficacy and safety of IV acetaminophen for use in tonsillectomy and FESS. We wish to provide a more comprehensive analysis of pain management in the setting of FESS in the following ways :

  1. by administering IV acetaminophen perioperatively (before start of surgery, and after surgery completion;
  2. by employing a pain score of 4 (whereas other studies use 3) as a cutoff for breakthrough pain; and,
  3. by addressing novel outcomes including patient sedation and patient satisfaction, in addition to opioid analgesic use.

In our institution, we have completed a preliminary pilot study exploring the use of intravenous anesthesia which included acetaminophen during bilateral endoscopic sinus surgery. Secondary outcomes measured during the study included:

  1. Pain
  2. Rescue analgesic use
  3. Nausea/Vomiting
  4. Time spent in recovery
  5. Successful discharge from the PACU and the Hospital

Our pilot data has reaffirmed that the procedure is overall benign, with few associated risks and adverse events. Of note, none of the patients in our preliminary study required admission to the hospital after surgery for further observation as a result of uncontrolled pain or nausea. Based on this experience, we would like to explore the efficacy of intravenous acetaminophen (Ofirmev), a non opioid/non steroidal analgesic, in endoscopic sinus surgery.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

62

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Texas
      • Houston, Texas, Vereinigte Staaten, 77030
        • The University of Texas Health Sciences Center at Houston

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 68 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion criteria:

  1. Patients undergoing surgical management for CRS (with or without polyps)
  2. Operating time must be at least 2 hours in duration.
  3. Number of sinuses involved must be 3 or greater

Exclusion criteria:

  1. History of hypersensitivity to acetaminophen
  2. End stage renal disease
  3. End stage liver disease
  4. History of chronic pain, or use of opioid medication in the previous two weeks
  5. Severe depression or anxiety
  6. Use of gabapentin or any other pain modulator
  7. History of acute sinusitis or mucocele
  8. History of seizures
  9. Known or suspected history of alcohol or drug abuse
  10. Known or suspected history of morphine intolerance

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: IV Acetaminophen
The experimental group will receive a preoperative dose of 1000mg IV acetaminophen over 15 minutes. This will occur at least 15 minutes before the start of surgery. Another 1000mg dose of IV acetaminophen will be administered 4 hours after the first dose. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
Andere Namen:
  • OFIRMEV (Cadence Pharamceutical, San Diego, USA)
Placebo-Komparator: Control
The control group (Placebo) will receive 100 mL of 0.9% normal saline in place of IV acetaminophen in the same manner as the experimental group; the investigator/physician in question will be blinded to the agent that is being administered. Patients will be discharged with instruction to continue APAP 500 mg PO every 6-8 hours. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
Andere Namen:
  • Normale Kochsalzlösung

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Pain Level Assessed Using a Visual Analogue Scale (VAS) Scale
Zeitfenster: 15 minutes and 120 minutes Post-Operatively
VAS is a validated, self-reported data sheet assessing average pain intensity. Possible scores range from 0 (no pain) to 10 (highest level of pain).
15 minutes and 120 minutes Post-Operatively

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Total Doses of Postoperative Opiate (Morphine) Use
Zeitfenster: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
The total amount of morphine utilized in Postoperative Acute Care Unit (PACU) will be recorded. One dose is a 1mg bolus of morphine.
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Number of Participants Who Received Intraoperative Supplemental Fentanyl
Zeitfenster: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Number of participants who received intraoperative supplemental fentanyl. The decision to administer fentanyl is based on hemodynamic changes, such as increasing blood pressure and heart rate.
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Number of Participants Who Experienced Postoperative Morbidity (Nausea)
Zeitfenster: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Post-operative nausea will be monitored and measured through direct observation and nursing clinical record
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Postoperative Vital Sign (Systolic Blood Pressure)
Zeitfenster: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Postoperative Vital Sign (Diastolic Blood Pressure)
Zeitfenster: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Postoperative Vital Sign (Pulse)
Zeitfenster: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Postoperative Vital Sign (Temperature)
Zeitfenster: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Postoperative Vital Sign (Respiratory Rate)
Zeitfenster: During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)
Postoperative vital signs (systolic and diastolic blood pressure, pulse, temperature, and respiratory rate) were measured at different time points up to 4 hours after surgery.
During Postoperative Acute Care Unit (PACU) stay (up to 4 hours after surgery)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Mitarbeiter

Ermittler

  • Hauptermittler: Davide Cattano, MD, PhD, The University of Texas Health Sciences Center at Houston

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Juli 2012

Primärer Abschluss (Tatsächlich)

1. September 2014

Studienabschluss (Tatsächlich)

1. September 2014

Studienanmeldedaten

Zuerst eingereicht

25. Mai 2012

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

29. Mai 2012

Zuerst gepostet (Schätzen)

31. Mai 2012

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

16. Oktober 2015

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

25. September 2015

Zuletzt verifiziert

1. September 2015

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Chronische Sinusitis

Klinische Studien zur IV Acetaminophen

3
Abonnieren